Objective: The purpose of this study was to assess the diagnostic value and safety of the contrast agent gadoterate meglumine (Gd-DOTA, DOTAREM, Guerbet, Roissy CdG Cedex, France) in the setting of a postmarketing surveillance study. Materials and Methods: Between January 2004 and October 2005, radiologists in 61 radiologic institutions were asked to document the routine use of Gd-DOTA in a questionnaire. In addition to assessing the image quality and diagnostic value of the contrast-enhanced magnetic resonance imaging scans, we statistically evaluated and analyzed demographic and safety data. Results: A total of 24,308 patients were intravenously injected with Gd-DOTA for various diagnostic examinations. The examination allowed for establishing a diagnosis in Ͼ99% of cases and image quality was rated as "excellent" or "good" in 97.5% of all cases. Adverse events were noted in only 0.4% of the examinations and were mostly rated as minor, such as feeling of warmth or taste alteration. There was one serious adverse event, albeit with complete recovery. Conclusion: This postmarketing surveillance study suggests diagnostic efficacy and a favorable clinical safety profile of Gd-DOTA in clinical practice.
M agnetic resonance imaging (MRI) is unique among currently available imaging techniques in that there are multiple parameters responsible for signal intensity that produce images with a rather high degree of soft-tissue contrast. Thus, it was initially speculated that there would be no need for contrast agents in MRI. However, its propensity to contrast material is far greater than that of x-ray computed tomography (CT). In the early 1980s, it became apparent that contrast enhancement substantially improved the sensitivity and specificity of MRI scans. Accordingly, it has been demonstrated that MRI benefits vastly from paramagnetic contrast media for the detection of blood-brain barrier disruptions as well as for further characterization of parenchymal lesions and lymph nodes. For example, many brain metastases can only be visualized after contrast enhancement, [1] [2] [3] [4] [5] and some hepatic lesions can only be classified by the way in which they take up contrast material. 6 -12 In addition, contrast media are essential for displaying the vascular system with fast 3-dimensional gradient-echo sequences. [13] [14] [15] [16] [17] The development of new hardware together with advances in contrast media design continue to drive the expansion of intravenous contrast media applications. 18 Currently, a variety of paramagnetic contrast agents are used for a broad spectrum of clinical indications, including gadoterate meglumine (Gd-DOTA, DOTAREM, Guerbet, Roissy CdG Cedex, France), a paramagnetic extracellular contrast agent used for enhancement of signal intensity in MRI. The compound is approved for imaging cerebral and spinal lesions with abnormal blood-brain barrier or anomalous vascularity as well as for body imaging. Gd-DOTA is a very stable and hyperosmolar agent (1350 mosm/kg H 2 O) with a gadolinium concentration of 0.5 mol/L, characterized by r1 and r2 values (determined experimentally at 20°C and a magnetic field strength of 1.0T) of 3.4 L (mmol ϫ s) Ϫ1 and 4.8 L (mmol ϫ s) Ϫ1 , respectively. The aim of this large-scale postmarketing surveillance study, which was conducted in Germany, was to assess the diagnostic quality and safety of intravenous injections of Gd-DOTA in patients who underwent routine MRI examinations.
MATERIALS AND METHODS

Patients
Demographic, clinical, imaging, and safety data from patients who underwent routine MRI examinations with intravenous administration of Gd-DOTA were obtained from board certified radiologists in 61 radiologic institutions throughout Germany between January 2004 and October 2005. Enrollment in the study was possible up to 1000 patients per study site (mean 394.61; median 399.5; mode 400). According to the summary of product characteristics, known allergies to gadoterate, meglumin, other Gd-drugs, or severe renal impairment (ie, creatinine clearance less than 30 mL/min) were contraindications. Therefore, those patients were not included in this study.
In view of the recommendations concerning observational studies issued by the German Federal Institute for Drugs and Medical Devices (BfArM) in 1998 19 and in accordance with the definition of a "noninterventional trial" in Article 2(c) of Directive 2001/20/EC, 20 the decision to include a patient in this observational study was completely independent of the decision to conduct an MRI examination, ie, the patient underwent the MR examination irrespective of the participation in this study. Gd-DOTA was to be used in accordance with the local approved Summary of Product Characteristics which is equivalent to the European package insert.
Data Collection
Patient data were collected through the use of standardized questionnaires completed by the radiologist. Patients' demographic data (age, sex, height, and weight, including calculation of body mass index ͓BMI͔, measured in kg/m 2 ) and the type of examination performed were recorded. In addition, information was collected on the number and type of relevant medical history, premedication administered; the intravenous contrast medium injection (dose, amount, and mode of administration, ie, manual/automated/single or repeated injection); subjective assessments of image quality (excellent, ie, superb and completely homogenous signal enhancement of target structures, evaluation possible with high diagnostic confidence; good, ie, good signal enhancement of target structures, almost completely homogeneous, evaluation possible with satisfactory diagnostic confidence; mediocre, ie, moderate signal enhancement of target structures, but still inhomogeneous, evaluation possible with low diagnostic confidence; bad, ie, low and inhomogenous signal enhancement of target structures); very bad (ie, no signal enhancement); and assessment of the diagnostic yield of the examination (yes/no) stating the reasons when the answer was "no." Adverse events spontaneously reported from the patient at any time were recorded as well as adverse events that were observed by the MR technologist, nurse, or physician. Details of any adverse events (type, duration, necessity of treatment, type of treatment) also were collected, including information on outcome and any indication of whether the examination had to be discontinued because of such events or whether a return to normal health status was achieved, as well as stating whether there was considered to be a causal relationship to the contrast medium. Each patient was monitored about adverse reactions during and for approximately 30 -60 minutes after the procedure.
Statistical Analyses
All data were typed in an electronic data sheet using Visual Stats AWB (version 2002). Concomitant medication was recorded, and adverse events were classified in accordance with World Health Organization Adverse Reaction Terminology. Based on the data of the postmarketing surveillance study, statistical analysis was done with SPSS for Windows using the 2 test according to Pearson. Whenever data were missing, the results were adjusted to 100% to allow for comparison of percentages. A P value less than 0.05 was considered statistically significant.
RESULTS
Patient Demographics
A total of 24,308 patients were included (10,924 men ͓44.9%͔ and 13,327 women ͓54.8%͔). The gender of 57 patients (0.2%) was not stated in the questionnaires. Patients ranged in age from a few weeks to 103 years (mean, 51.8 years). A total of 4907 (20.2%) of the patients were classified as having relevant medical history. The most common risk factors were known allergies (including to iodinated contrast material), arterial hypertension, coronary artery disease, and asthma ( Table 1) .
Types of Examinations
In 13,668 patients (56.2%), the contrast-enhanced MRI study was performed for neuroradiological purposes, body MRI studies were performed in 2743 patients (11.3%), and musculoskeletal MRI with contrast material enhancement was performed in 28.8% (n ϭ 7009).
Contrast Medium Injection
The Gd-DOTA contrast medium was injected manually in a majority of cases (76.0%), whereas automated intravenous injection was performed in 24.0% of cases. Most of patients received a single injection of Gd-DOTA (98%) and the average dose was 0.1 mmol/kg. The injected volume of Gd-DOTA per patient ranged from 0.6 mL in a newborn to 80 mL in an obese woman, the average volumes injected varied with the type of examination and were bodyweight-adjusted. For the entire study cohort, a mean volume of 15.8 mL of Gd-DOTA was injected per examination. A mean dose of 0.1070 mmol/kg was intravenously injected (95% confidence interval, 0.1067; 0.1074). Comparison of contrast medium volumes and the patients' weight with subdivision into patients with normal weight and those with overweight according to the conventional, age-related limits of the body mass index (BMI) showed that patients with a BMI above 
Subjective Assessment of Image Quality and Diagnostic Yield
The question referring to the diagnostic yield was not answered in 217 patients (0.9%). The remaining patients were adjusted to 100%, of which a total of 23,993 (99.6%) were of diagnostic quality and 98 (0.4%) were classified as nondiagnostic. Subjective assessment of the image quality was missing in 221 questionnaires (0.9%). The results of the remaining 99.1% of cases (again adjusted to 100%) are presented in Table 2 . Image quality was rated as "excellent" or "good" in 23,490 cases (97.5%). Image quality was statistically significantly worse in patients with overweight (BMI Ͼ 25) (P Ͻ 0.001). Further analysis of the reasons given for rating image quality as nondiagnostic revealed that technical problems were the primary cause in only 16 of the 98 cases (0.1% of all examinations). Movement and/or lack of cooperation from the patient during the examination were involved in 58 cases (0.2%) and, in 38 cases (0.2%), a detailed reason for the poor image quality was not declared.
Adverse Events
Minor adverse events associated with Gd-DOTA occurred infrequently and included nausea, feeling of warmth, and taste alteration. Adverse events were reported in a total of 94 patients (0.4%), and the most frequently occurring adverse events are listed in Table 3 . There were no statistically significant differences between the subgroups of the study population for any adverse event, except for patients with liver disease. Those experienced nausea after injection statistically significantly more often than any other subgroup (P Ͻ 0.001). Only one reaction led to discontinuation of the examination (0.004%), and all other examinations were routinely terminated. Twenty-four patients (25.5%) with adverse reactions required further medical treatment of the adverse event, including one who required hospitalization (1.1%). Complete recovery was achieved in 58 patients who reported adverse events (61.7%), 1 case (1.1%) was classified as unknown outcome, and in 34 cases (36.2%) it was not stated whether symptoms persisted. All documented subsequent courses were uneventful. In 2 (2.1%) patients the experienced adverse events were classified as not related to the administration of the contrast agent. In 63 (67%) patients, these were considered to be most likely related to the injection of the agent. In 29 cases (30.9%) the causal relationship to Gd-DOTA was not mentioned.
In 1 of 24,308 patients (0.004%), a serious adverse event occurred that was considered to be life-threatening. This 65-year-old man with no known allergies underwent an MRI examination with intravenous injection of 17 mL of Gd-DOTA for assessment of cervicobrachalgia (pain in the area of cervical vertebra spreading to the left arm) and cervical myelopathy on May 17, 2004 . His medical history included alcohol and drug abuse (not specified further), symptomatic transitory psychotic syndrome, coronary artery disease with status post angioplasty, and stent implantation into the of the left anterior descending coronary artery. He also had a history of an occluded left-sided femoro-femoral arterial bypass grafting, hypercholesterolaemia, and gastric surgery (not specified further), and peripheral arterial occlusive disease was diagnosed in 1998, which had been treated with phenprocoumon. The patient did not show effort angina, arrhythmias, or known thyroid disorders. On the day of the examination, he was treated with diazepam and a 50-mL injection of NaCl (0.9%). Immediately after the Gd-DOTA injection, he experienced anaphylactic shock associated with nausea, eructation, pallor, perspiration, and convulsions. His pulse decreased, and ventricular fibrillation was recognized. He was immediately transferred to the intensive care unit (ICU) of the hospital, where corrective treatment was initiated and resuscitation and intubation were performed. In the ICU, the patient was diagnosed with an acute coronary syndrome and, during conventional coronary angiography on 18 May 2004, 4 stents were successfully implanted in the right coronary artery. After this intervention, the patient was reported to be stable. The final outcome was favorable with complete recovery. According to the hospital physician, an anaphylactic reaction caused by the administration of contrast medium seemed to be possible based upon the history (the patient's health status deteriorated immediately after the injection of Gd-DOTA with consecutive shock) but could not be definitely established. It is most probable that the acute symptoms were caused by an acute occlusion of the right coronary artery caused by pre-existing coronary artery disease; however, the anaphylactic reaction to the contrast medium may have triggered this critical situation. 
DISCUSSION
This postmarketing surveillance study has provided the largest analysis of tolerance, adverse reactions and diagnostic yield with the use of Gd-DOTA since its introduction into clinical practice. Overall, Gd-DOTA was shown to have a favorable tolerability profile and it also permitted diagnostic examinations in Ͼ99% of injections. A single serious adverse event was observed among Ͼ24,000 injections and image quality was rated as excellent or good in almost all cases (97.5%).
Because a very high degree of soft-tissue contrast is an inherent benefit of MRI, it might be anticipated that no further benefit, in terms of both image quality and diagnostic confidence, could be derived from the use of additional contrast material. However, the use of paramagnetic contrast agents has dramatically improved the diagnostic sensitivity and specificity of MRI for evaluating diseases of the central nervous system, parenchymal organs and especially the vascular system. Gd-DOTA was shown in this study to provide a combination of both diagnostic information and diagnostic confidence, while being generally well tolerated, in line with other paramagnetic contrast agents. In view of this, the use of Gd-DOTA-enhanced MRI should be considered among the range of diagnostic first-line imaging strategies, according to the suspected disease at hand.
Adverse events may be associated with the administration of any given medication in clinical practice. However, as contrast media are always critical in this regard since the majority of examinations are mere diagnostic procedures, one must always outweigh the risks of the agent against the benefits. Thus, any contrast material should be administered cautiously, especially in patients with a known history of allergy or asthma. In particular, attention should be focused on patients who have a known history of reaction to a contrast agent. In comparison with x-ray compounds, the number of such events is exceptionally low for MRI contrast agents. 21 Interestingly, patients with a history of adverse reaction to an iodinated contrast agent also are at a slightly greater risk of reacting to injection of a paramagnetic contrast agent. In addition, MRI contrast agents in the doses used for MR imaging lack the nephrotoxicity associated with iodinated contrast media. 22 A particular strength of this postmarketing surveillance study was that it allowed data on tolerability to be collected from a patient population that included a significant proportion of patients with risk factors for adverse reactions to contrast agents.
The results of this analysis have been consistent with the findings of previous studies of Gd-DOTA published by other study groups that included fewer patients. For example, in a study of 1038 patients, Oudkerk et al found that minor adverse events occurred in 0.97% of patients after the injection of Gd-DOTA for MRI studies of the brain and the rest of the body. 23 Adverse events were reported in 17.3% of patients after the administration of Gd-DOTA in a study that included only 300 unselected neurologic patients. The fact that the frequency of adverse events in this postmarketing surveillance study was lower than in this rather small clinical study may have been at least partially due to the latter investigators being more cautious in their approach than the investigators in routine clinical practice who collected the data reported in the present study.
Safety studies that have provided a comparable degree of patient exposure have been performed with other paramagnetic contrast agents such as gadopentetate dimeglumine (ie, Gd-DTPA, Magnevist, Schering, Berlin, Germany), which was the first paramagnetic MRI contrast agent to be marketed in Europe and the United States in 1988. 24 -28 Gd-DOTA has been reported to be similarly well tolerated and both agents have been shown to possess similar diagnostic efficacy. 21 More recently, new contrast agents have become available and been subject to safety evaluations in smaller preclinical and clinical studies. 29, 30 The present study is not without its limitations. For example, the use of questionnaires for data collection in a postmarketing surveillance study limits the quality of the results compared with study designs such as controlled clinical trials because the responses to the questions are affected to some extent by the subjective assessment of the investigator. On the other hand, a surveillance study by questionnaire allows for collection of data from a very large and truly representative study population. Hence, it is possible to also identify very rare events (such as one severe adverse event in our population of over 24,000 patients). Indeed, in the present study, the overall incidence of reported adverse events was only 0.4%. The most significant limitation of this evaluation, as with most multicenter studies of contrast agent safety, is a consequence of the inevitable variability among different investigators in relation to the responses of patients about adverse reaction occurrences and how they are elicited. In addition, adverse events which occurred later than 24 hours after Gd-DOTA-enhanced MRI might have been missed as investigators did not initiate the contact after that timepoint. Thus, it seems likely that some mild adverse events may have been underreported in this patient cohort. In addition, this study might be different from previous surveys in methods of eliciting adverse events. Finally, the use of subjective assessments of image quality may have introduced variability and bias to the study.
In conclusion, the experience with Gd-DOTA compiled in this postmarketing surveillance study in more than 24,000 patients, including a significant proportion of patients with risk factors for adverse reaction to contrast agents, has demonstrated both the favorable clinical safety profile as well as the excellent clinical efficacy of this contrast agent.
